Development of medicinal seeds for Alzheimer's disease based on the structural analysis of toxic oligomers of amyloid beta

点击翻译按钮获取中文摘要

Aggregation of the 42-mer amyloid beta peptide (Abeta42) plays a critical role in the pathogenesis of Alzheimer's disease (AD). We have recently identified the toxic turn at Glu-22 and Asp-23 of Abeta42. Based on the toxic turn, we developed a new antibody 11A1 that selectively recognized the toxic trimer as well as the intracellular Abeta which could not be detected by commercially available Abeta antibodies. Therefore, 11A1 might become a diagnostic drug for AD. By contrast, we found that catechol-type flavonoids could specifically suppress Abeta42 aggregation by targeting the Lys-residues.